TG Therapeutics (TGTX) Competitors $29.44 +0.67 (+2.33%) Closing price 04:00 PM EasternExtended Trading$29.48 +0.04 (+0.15%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. GMAB, VTRS, RDY, ASND, MRNA, QGEN, BBIO, VRNA, ELAN, and BPMCShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Its Competitors Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Qiagen BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Genmab A/S (NASDAQ:GMAB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Do analysts recommend GMAB or TGTX? Genmab A/S currently has a consensus target price of $37.60, suggesting a potential upside of 52.54%. TG Therapeutics has a consensus target price of $46.25, suggesting a potential upside of 57.10%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor GMAB or TGTX? In the previous week, Genmab A/S had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for Genmab A/S and 7 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.18 beat Genmab A/S's score of 0.70 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in GMAB or TGTX? 7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 10.6% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, GMAB or TGTX? Genmab A/S has higher revenue and earnings than TG Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B5.06$1.14B$1.9912.39TG Therapeutics$454.07M10.29$23.38M$0.3779.57 Which has more volatility and risk, GMAB or TGTX? Genmab A/S has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Is GMAB or TGTX more profitable? Genmab A/S has a net margin of 37.53% compared to TG Therapeutics' net margin of 13.31%. TG Therapeutics' return on equity of 26.05% beat Genmab A/S's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% TG Therapeutics 13.31%26.05%9.58% SummaryTG Therapeutics beats Genmab A/S on 9 of the 17 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.67B$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio79.5721.1431.1525.96Price / Sales10.29398.37475.15122.97Price / Cash235.9943.0937.1558.38Price / Book16.928.079.116.39Net Income$23.38M-$54.72M$3.26B$265.56M7 Day Performance4.84%2.62%2.11%1.98%1 Month Performance-21.22%7.63%5.12%1.33%1 Year Performance20.66%13.11%31.25%21.15% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics4.3598 of 5 stars$29.44+2.3%$46.25+57.1%+14.8%$4.67B$454.07M79.57290Positive NewsGMABGenmab A/S3.8791 of 5 stars$23.42+0.5%$37.60+60.5%-11.2%$15.02B$3.12B11.772,682Positive NewsAnalyst DowngradeVTRSViatris1.6948 of 5 stars$10.63+0.2%$10.40-2.2%-8.8%$12.39B$14.74B-3.6732,000RDYDr. Reddy's Laboratories3.129 of 5 stars$14.26+0.2%$16.95+18.9%-14.5%$11.90B$3.81B21.6027,811ASNDAscendis Pharma A/S3.3407 of 5 stars$194.08-2.1%$242.93+25.2%+40.7%$11.88B$393.54M-37.611,017News CoveragePositive NewsAnalyst ForecastMRNAModerna4.4392 of 5 stars$28.09+0.2%$43.59+55.2%-69.7%$10.93B$3.24B-3.735,800Analyst ForecastQGENQiagen3.8337 of 5 stars$48.66-1.4%$49.69+2.1%+7.4%$10.82B$1.98B28.755,765BBIOBridgeBio Pharma4.7461 of 5 stars$49.02-4.5%$61.35+25.2%+96.5%$9.37B$221.90M-11.99400Positive NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share2.4678 of 5 stars$105.79+0.5%$109.00+3.0%+276.7%$9.01B$42.28M-106.8630Positive NewsShort Interest ↓ELANElanco Animal Health3.1498 of 5 stars$17.72-1.4%$17.33-2.2%+17.8%$8.80B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.5049 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640 Related Companies and Tools Related Companies Genmab A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access